When studying IL-4, an increase in this indicator was found in patients with gastric cancer at stages I, II, and III of the disease compared to the control group and the group of patients at stage IV of the disease (p1–2 < 0.001, p1–3 < 0.001, p1–4 < 0.001). Here, IL4 is linked to gastric cancer.